Table 4.
Logistic regression analysis of patients with acute myocardial infarction undergoing coronary intervention (n = 309).
| B | SE | Wald c2 | p value | OR | 95% CI | |
|---|---|---|---|---|---|---|
| Evolocumab | 1.62 | 0.46 | 12.65 | <0.01 | 5.07 | 2.07–12.39 |
| Killip class I | −1.26 | 0.78 | 2.59 | 0.11 | 0.29 | 0.06–1.31 |
| Hs-CRP | <0.01 | 0.01 | <0.01 | 0.99 | 1.00 | 0.99–1.02 |
| Emergency PCI | 0.31 | 0.44 | 0.51 | 0.47 | 1.37 | 0.58–3.22 |
| Age >70 years | -0.55 | 0.42 | 1.76 | 0.19 | 0.58 | 0.26–1.30 |
| Hypertension | −0.23 | 0.44 | 0.28 | 0.60 | 0.80 | 0.34–1.85 |
| LVEF <45% | −0.58 | 0.42 | 1.87 | 0.17 | 0.56 | 0.25–1.28 |
| Anemia | −0.09 | 0.87 | 0.01 | 0.92 | 0.92 | 0.17–4.99 |
| Diabetes mellitus | −1.09 | 0.40 | 7.50 | <0.01 | 0.34 | 0.15–0.73 |
| Previous MI | 0.10 | 0.48 | 0.04 | 0.84 | 1.10 | 0.43–2.80 |
| Contrast medium dose >150 mL | −0.44 | 0.51 | 0.76 | 0.39 | 0.64 | 0.24–1.74 |
| Iodixanol | −0.13 | 0.73 | 0.03 | 0.86 | 0.88 | 0.21–3.70 |
B, beta; SE, standard error; OR, odds ratio; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; MI, myocardial infarction.